Third Implantation of Device Firm’s Total Artificial Heart That ‘Could Save Many Patients Who May Die’

August 31, 2021 ( Newswire) An H.C. Wainwright & Co. report noted that Carmat’s Aeson implant “could save many patients who may die, due to [a] shortage of donor hearts, while waiting for a heart transplant.”


In an Aug. 27 research note, H.C. Wainwright & Co. analyst Yi Chen reported that the third implant of Carmat SA’s (ALCAR:PA; CKMTF:OTCMKTS) Aeson bioprosthetic artificial heart, intended to be a bridge to transplant, was just carried out.

The implant recipient had severe end-stage biventricular heart failure and qualified for an urgent heart transplant, Chen noted. The patient is recovering well post-procedure.

This third commercial Aeson implantation was performed at the Department of Cardiovascular Surgery at the University Medical Center Schleswig-Holstein, one of Germany’s premier heart centers. The second Aeson also had been implanted in Germany, at the Hannover Medical School, whereas the first had been done in Italy.

“Observations thus far validate Aeson’s clinical utility and bode well for the commercial prospects in the European Union,” commented Chen. “We expect to see additional implants of Aeson as a bridge to transplant in Germany in the coming months.”

In other Aeson news, out of the U.S., the second center implanted the artificial heart as part an early feasibility study being conducted, Chen indicated. The procedure was carried out at University of Louisville Health-Jewish Hospital in Kentucky. The first had been done at Duke University Hospital in North Carolina in July 2021.

For the U.S. feasibility study, a total of 10 patients will be enrolled. Per the protocol, a report on the first three implanted patients must be generated after 60 days post-implantation and before enrollment of the remaining seven patients. The study’s primary endpoint is survival 180 days after implant or a successful heart transplant within 180 days post implant. Topline data are expected in mid-2022.

Chen highlighted that Aeson could save many patients who otherwise would die while waiting for a rare available heart and transplant.

“Aeson’s differentiated features, including hemocompatibility, pulsatility, autoregulation, and silent operation, have the potential to enable a genuine physiologic heart replacement therapy for critically ill patients suffering from end-stage biventricular heart failure [and] who have few options,” Chen wrote.

H.C. Wainwright & Co. has a Buy rating and a EUR38 per share price target on France-based Carmat. Its current share price is about EUR27.25.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

More Info: Newswire

This news is published on the Newswire – a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy:

Follow Us on StockTwits - A Leading Global Investor Website for Biotech Industry Stocks – investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Buy a biotech guest post on

What's your reaction?

In Love
Not Sure

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News


Another One Bites the Dust

January 20, 2022 ( Newswire) S&P 500 gave up opening gains that could have lasted ...
Next Article:

0 %